c. Elimination of heat and moisture, thus increasing not only the stability but also the suitability of the process for thermolabile and moisture sensitive API. d. Particle size uniformity. e. Prime particle dissolution. 
Direct compression process of Tablet

II.
Materials and Methods
a. Pre formulation Studies
Pre formulation study is an investigation of physical and chemical properties of a drug substance alone and when combined with excipients. It is the first step in the rationale development of dosage form.
Estimation of  max of Eszopiclone
Estimation of  max of Eszopiclone by Ultraviolet absorption spectrophotometry method based on the measurement of absorbance at spectral range of 200 to 380 nm of U.V. region. Medium: methanol
Preparation of solution
Weigh accurately about 25.0 mg of Eszopiclone standard, in a 50 ml volumetric flask add 40ml of methanol dissolve and dilute to the volume with Methanol and take 1ml of above solution in 100ml volumetric flask and dilute to the volume with methanol.
Calibration Curve for the Estimation of Eszopiclone
Spectrophotometric method based on the measurement of absorbance at 305 nm of U.V. region was used in the study for estimation of Eszopiclone. 
Stability Studies
The stability of pharmaceutical ingredients and the products containing them depends on two major factors: a) The chemical and physical properties of the materials concerned (including the excipients and container closure systems used for packaging of formulated products). b) Environmental factors, such as temperature, humidity and light and their effect on the drug products.
Frequently, the goal of a pharmaceutical company is to develop a globally acceptable registration stability protocol. A sound stability protocol not only eliminates unnecessary testing but also reduces manufacturing needs, cost and time. This is especially important in current scenario due to increase in the number of possible storage conditions and checkpoints because of stringent regional requirements.
Generally, a finished product should be evaluated under storage conditions that test its thermal stability and if necessary its sensitivity to moisture and potential for solvent loss.
The table below gives the information about the types of stability studies on which the drug is to be loaded.
Study Storage condition Minimum time period
Long 25°C ± 2°C/60% RH ± 5% RH 30°C ± 2°C/65% RH ± 5% RH 6 months 12 months Intermediate 30°C ± 2°C/65% RH ± 5% RH 6 months Accelerated 40°C ± 2°C/75% RH ± 5% RH months In the present study the finished products are loaded for accelerated stability studies.
Formulation and Evaluation of Eszopiclone Film Coated Immediate Release Tablets by ….
Stability studies were conducted for the film coated formulations at 40ºc± 2°C / 75% RH± 5% RH for about 3 months in stability chamber (Thermo lab). Samples were analyzed for assay, dissolution and water by kf.
III.
Results 
Pre formulation studies
From the above data we can conclude that the Eszopiclone complies with all the specifications mentioned above. Eszopiclone is white in colour and soluble in 0.1N HCl, weakly soluble acetate and phosphate buffer mediums. From physico mechanical characterization we found that Eszopiclone has a good flow properties which plays an important role in the selection of tablet manufacturing process and since, the flow properties are good and as the market product has used the direct compression method in the manufacture of tablet, we also use the same process in the manufacture of Eszopiclone film coated tablets. By compatibility studies it is clear that there is no interaction between the drug and excipients. And even between the excipients. 
IV. Summary and Conclusion
The study was undertaken with the aim to develop a stable form of Eszopiclone by Immediate release drug delivery.
The API, Eszopiclone was selected and formulated as immediate release film coating tablets of 3, 2 and 1 mg and their dissolution profiles were compared with the dissolution profile of market products product i.e., LUNESTA ® . In the present work pre-formulations were conducted to know the drug excipient compatibility and to generate information useful to the formulation development for a stable and bioavailable dosage forms. Based on the results suitable excipients were selected for formulation development. During pre-formulation the parameters bulk density, tapped density, Carr's index and Hasner's ratio, angle of repose, particle size analysis and solubility.
Tablets were prepared by direct compression technique. During development of formula various inprocess tests such as weight variation, hardness, thickness and disintegration time were evaluated. Core tablets were coated with coating suspension to 12%. Finished products were evaluated for dissolution, water content and assay. The developed trails were tested for invitro dissolution profile and compared with the reference product LUNESTA ® . The invitro dissolution profile of formula 8 for 3mg (formula 9 for 2mg and formula 9 for 1mg) was similar to that of reference product, LUNESTA ® . The optimised batch tablets were packed in HDPE (High Density Poly Ethylene) containers and performed stability studies at 40°C / 75% RH. Stability studies were evaluated initially, 30 days and 60 days. The results were compared with the predetermined specifications. All the results were found to be satisfactory. Hence the developed formula was stable.
The objective of the present project was successfully achieved by developing the product, giving the same release profile to that of market products product, LUNESTA ®
